Open Clinical Trials

DiseaseTrial NumberName of TrialDrug & Link to clinicaltrials.gov
ImmunotherapyNSH1150Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High-Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell TransplantationPembrolizumab NCT02771197
NSH1164A Phase I Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb® 14045 in Patients With CD123-Expressing Hematologic MalignanciesXmAB® 14045 NCT02730312
NSH1170A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells, in Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma JCAR017 NCT02631044
AMLNSH1144A Phase 2, Randomized, Biomarker-Driven, Clinical Study in Patients With Relapsed/Refractory AML With an Exploratory Arm in Patients With Newly Diagnosed High-Risk AMLAlvocidib
NCT02520011
 NSH1164A Phase I Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb® 14045 in Patients With CD123-Expressing Hematologic MalignanciesXmAB®
14045 NCT02730312
 NSH1169A Phase I/II Study of SEL24 in Patients with Acute Myeloid LeukemiaNCT03008187
NSH1190A Efficacy Study of Inecalcitol in Combination with Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy Chemotherapy in Patients With Relapsed or Refractory AML With FLT3 Mutation Inecalcitol
NCT02802267
 
ALLNSH1099E1910: Phase 3 Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL Negative B-ALL in AdultsBlinatumomab
NCT02003222
 
 B-Cell MalignanciesNSH1170A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells, in Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma NCT02631044
 
 TransplantNSH1074A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed by Maintenance Therapy with the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-Risk Hematologic Malignancies.MLN9708
NCT02169791
 NSH1107A Phase II Trial of High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Upfront Treatment of Multiple MyelomaBendamustine
NCT02416206
NSH1125A Multicenter Phase II, Double-Blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Multiple Myeloma BMT CTN 1302Ixazomib
NCT02440464
NSH1132A Phase II Trial of Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic MalignanciesFludarabine
Melphalan Cytoxan NCT02581007
NSH1150Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High-Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell TransplantationPembrolizumab
NCT02771197
NSH1158A Study of T Cell Replete, HLA-Mismatched Bone Marrow Transplantation With Post-Transplant Cyclophosphamide as a Front-Line Therapy for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related DonorFludarabine
Cyclophos NCT02828592
NSH1184Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients With Symptomatic Sickle Cell Disease NCT03263559
C282Alliance A051301 – A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell SubtypeIbrutinib
NCT02443077
 
 Post TransplantNSH1182BMT CTN 1506 Randomized Trial of FLT3 Inhibitor vs Placebo as Maintenance Therapy Post Allogeneic Transplant Gilteritinib
NCT02997202
 
Supportive Care/OtherNSH721NMDP Recipient Consent for Participation in Registry, Research Database, and Research Sample Repository NCT00495300 (sample)  NCT01166009 (database)
 NSH943A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other IndicationsNCT01351545
NSH995A Multicenter Safety Study of unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric
and Adult Patients
NCT01656603
NSH 1188Non-Treatment research protocol to procure patient-derived blood and tissue samples